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Summary 
Mice mutant for granulocyte macrophage colony-stimulating factor (GM-CSF) or the com- 
mon receptor component ([3c) for GM-CSF, interleukin (IL)-3, and IL-5 exhibit a lung disor- 
der similar to human pulmonary alveolar proteinosis, a rare disease  with congenital, infantile, 
and adult forms. Bone marrow transplantation and hematopoietic reconstitution of ~c mutant 
mice with wild-type bone marrow reversed the established disease  state in the lungs, defining 
this  disease  as  hematopoietic in nature.  It is likely that the  disease  involves alveolar macro- 
phages, as donor myeloid cell engraftment into the lungs of mutant recipient mice correlated 
with reverting both the disease and an abnormal macrophage morphology seen in the lungs of 
affected animals.  Recombination Activating Gene-2 mutant donor bone marrow, which lacks the 
potential to develop lymphocytes, reversed the pathology in the lungs to the same extent as 
whole bone marrow. These data establish that certain lung disorders, if of cell-autonomous he- 
matopoietic origin, can be manipulated by bone marrow transplantation. 
p ulmonary alveolar proteinosis (PAP) is a rare lung dis- 
ease where periodic acid SchitYs reaction (PAS)-posi- 
rive material  is  progressively accumulated  in  the  alveolar 
space  (1).  The intraalveolar material is pulmonary surfac- 
tant,  a mixture of surfactant proteins (SP-A, B, C, and D) 
and phospholipids (2).  Human PAP is classified  into three 
categories: adult,  infantile, and congenital forms.  The in- 
fantile and congenital forms lead to early respiratory failure, 
and the prognosis is poor (3). Adult type is not as severe, 
but can be complicated by opportunistic infection (1). 
Gene knockout techniques have provided a number of 
mouse models that are similar to human diseases.  One ex- 
ample is the PAP-like disease  in mice that harbor targeted 
mutation in the GM-CSF ligand (4, 5) or the [3c receptor 
gene (receptor for GM-CSF, IL-3, and IL-5)  (6, 6a).  The 
lungs of the  ~c receptor mutant mice show a progressive 
accumulation  of PAS-positive proteinaceous substance  in 
the alveolar spaces,  as well as peribronchovascular lympho- 
cyte infiltration. 
The morphology of alveolar macrophages in the lungs of 
the  mutant mice is grossly abnormal.  These macrophages 
are expanded by cytosolic ingested material and appear dis- 
tended and  foamy.  It is  therefore possible  that  GM-CSF 
produced in the lung may be a necessary signal through the 
[3c  receptor for the  appropriate  degradation  of suffactant 
internalized in alveolar macrophages. Alternatively, as type 
II pneumocytes are also  involved in surfactant production 
and resorption (7), a nonhematopoietic basis to the disease 
is also possible. 
If alveolar macrophages are a primary cause of the lung 
disease in [3c receptor mutant mice because of a cell-auton- 
omous defect, it should be possible to manipulate the lung 
disease by bone marrow transplantation. It has been shown 
that alveolar macrophages are derived from bone marrow 
precursors in rodent systems (8, 9), and also in humans (10). 
Although steady-state hematopoiesis of [3c mutant mice ap- 
peared normal, except for reduced levels of eosinophils (6), 
we  sought  to  explore the  relationship  between  the  lung 
disease  and  the  hematopoietic  system  by  bone  marrow 
transplantation studies.  The data presented define that [3c- 
deficient PAP is hematopoietic in nature,  and is likely to 
involve alveolar macrophages. 
Materials and Methods 
Mice.  All animals used in this study were raised and housed in 
microisolator cages at the DNAX Research Institute animal facil- 
ity. The production of the Bc mutant animals has been described 
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typical mouse pathogens. Wild-type (WT) and [3c mutant donor 
and recipient animals were derived from littermate-matched off- 
spring and represent an F  3 generation of 129  ￿  C57B1/6  back- 
ground. In other identical experiments, the WT animals used as 
bone marrow donors were of an F1 (129  ￿  C57B1/SJL)  genetic 
backgound. These WT F~ donor cells were haplocongenic at the 
Ly 5 locus (Ly 5.1  and Ly 5.2), due to the C57B1/SJL  congenic 
parent, allowing marking of the donor versus recipient cell popu- 
lations (11). Recombination Activating Gene-2 (RAG-2) mutant 
animals used for donor cells were of 129 genetic background. 129, 
C57B1/6, and C57/SJL are matched for H-2  b. 
Bone Marrow Transplantation.  Recipient  mace  were  irradiated 
by two doses of 600 rad, 12-16 h apart, from a 137Cs source. After 
irradiation, animals were  injected intravenously with  106  bone 
marrow  cells.  Marrow  cells were flushed out  of the  femur and 
depleted of RBCs by osmotic shock. All recipient animals were 
2-3-mo  old at the time of transfer except for the  recipients in 
R.ag-2 transfer experiment where animals were 7-too old. All do- 
nor animals were 2-3-mo old. 
Lung Pathologic Evaluation.  Lung  sections were  prepared for 
pathology and stained with either hematoxylin and eosin or with 
PAS as previously described (6). After transplantation at the indi- 
cated time periods, random step sections from each mouse (mini- 
mum of three) were prepared and placed into a histopathological 
category. 
Cell Preparation  from  Bronchoalveolar Lavage, Immunohistochemis- 
try, and Protein Determination.  Animals were killed and lungs were 
washed with PBS three times by inserting thin tubing attached to 
a  syringe into  the  trachea.  Centrifuged bronchoalveolar lavage 
(BAL) cells were cytospun and stained with Wright-Giemsa. For 
immunohistochemistry, lung tissue was fixed with 4% paraform- 
aldehyde in PBS overnight at 4~  embedded into  OCT  com- 
pound, and cut into 6-p,m-thick sections. After blocking endoge- 
nous  biotin and peroxidase, the  samples were  treated with  5% 
mouse serum for 30 rain at room temperature, stained with bio- 
tinylated anti-Ly 5.2 antibody for 1 h  at room temperature, de- 
veloped using a  LSAB  kit  (DAKO,  Glostrup,  Denmark),  then 
counterstained with hematoxylin. 
For determination of protein in the BAL fluid, the lungs were 
washed three times with a total volume of 3 ml PBS.  BAL fluid 
was centrifuged to remove cells and the total protein concentra- 
tion  was  determined  using  a  BCA  protein  assay  kit  (Pierce, 
Rockford, IL). 
Peripheral Blood Staining.  Peripheral blood was prepared by car- 
diac puncture, and RBCs were lysed by anamonium chloride. Cells 
were  incubated at  4~  with PBS  containing 3%  mouse  serum 
with FITC-conjugated anti-Ly 5.1 and biotinylated anti-Ly 5.2 anti- 
bodies  for  30  min,  and  then  with  PE-conjugated  streptavidin 
(Becton Dickinson &  Co.,  Mountain  View,  CA)  for  30  rain. 
Cells were washed and analyzed on a FACScan  |  machine (Bec- 
ton Dickinson & Co.). 
Results  and Discussion 
Bone Marrow Transplantation.  To address the potential link 
between hematopoiesis and the lung pathology in [3c mu- 
tant mice, bone marrow from WT  animals was transferred 
into lethally irradiated [3c mutant recipient animals in an at- 
tempt to cure the PAP. Mice were evaluated at 8 and 12 wk 
after bone marrow transplantation. 
In control experiments, transfer of WT  donor cells into 
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WT  recipient animals resulted in lung physiology similar to 
that  of unmanipulated WT  animals  (Fig.  1 a).  Transfer of 
J3c mutant bone marrow to [3c mutant recipient animals re- 
sulted in the typical PAP pathology of discreet intraalveolar 
material in the alveolar spaces (Fig. 1 b). However, transfer 
of WT  bone  marrow  into  [3c  mutant  recipient mice  re- 
suited in a striking improvement in the lung pathology at 8 
and  12  wk after transfer  (Fig.  1  c).  The  intraalveolar sub- 
stance  defining PAP was  completely absent or only resid- 
ual,  and in clear contrast to  the pathology observed in J3c 
mutant  animals  that  received  [3c  mutant  bone  marrow 
(compare Fig. 1 b to c). To quantitate the reversal of PAP, 
we performed multiple step sections of the lungs of each of 
the animals in the three transplanted groups described above. 
A  pathological evaluation  of each  of these  tissue  sections 
was done by placing each specimen into a histopathologic 
category  of  1  (normal  lung)-5  (severe  lung  pathology). 
(The  characteristics of each  category are  described in  the 
legend to  Fig.  2.)  Fig.  2  shows  that  the  WT  animals that 
had received WT  bone marrow were classified as category 
1  or  2.  [3c  mutant  animals  that  had  received  [3c  mutant 
bone marrow were classified as category 4  or 5.  [3c mutant 
animals that received WT  donor bone marrow were classi- 
fied as categories 2 or 3 at 8 wk after transplant and as cate- 
gory 3 at 12 wk after transplant. 100% of the [3c mutant an- 
imals that  received WT  bone  marrow  completely cleared 
the intraalveolar material, the defining characteristic of PAP. 
However,  as the  13c mutant  animals were  undergoing the 
disease state before transplant, residual damage to the lung 
tissue was detected after clearance of the disease state, as de- 
scribed below. 
The histopathologic category of the lung specimens from 
animals  cured  of PAP  (WT  to  J3c  mutant  transplanted 
group) was not identical to the animals of the WT  to WT 
transplanted  group.  The  types  of changes  accounting  for 
this  difference were  independent  of the  characteristics of 
PAP and consisted of two general findings. Areas of focal al- 
veolar macrophage accumulation (and possibly type II pneu- 
mocytes) were  detected. The arrows in Fig.  1 c show this 
cellular accumulation visualized by hematoxylin and eosin 
staining, and the arrows in Fig. 1 d show that the focal ac- 
cumulation  of cells contain  PAS-positive material.  Other 
changes  in  the  lung  where  the  disease  was  reversed  in- 
cluded  occasional  areas  of collapsed  alveolar septa  and  a 
limited amount  of fibrosis (data not  shown).  Collectively, 
the changes in the lung that distinguish WT  to [3c mutant 
transplanted groups from WT  to WT  transplanted groups 
are distinct from the progressive pathology of PAP, and may 
be indicative of reparative processes that accompany the re- 
versal of PAP, as well as the remains of direct damage caused 
to the lung tissue during the disease state. 
Protein  Accumulation  Was  Reversed  in  WT  to  tic  Mutant 
Transplanted  Animals.  To independently veil@ that the dis- 
ease was reversed, a group of WT  to [3c mutant animals was 
killed 10  wk after transplant,  and  total protein from BAL 
fluid was  determined.  Table  1  shows  that  the  amount  of 
protein in the lungs of WT  to [3c transplanted animals was 
indistinguishable from that of unmanipulated WT  animals, 
Bone Marrow Transplant Cures [3c-deficient Pulmonary Alveolar Proteinosis Figure 1.  kepresentative  pathology of the lungs of animals evaluated 8 wk after bone marrow transplantation. (a) WT to WT transplantation. (b) pc 
mutant to [3c mutant transplantation. (c) WT to [3c mutant transplantation. (d) PAS staining of WT to [3c mutant transplantation. Arrows in c and d high- 
light areas of focal accumulation of macrophages in WT to [3c transplantation. Lung sections were stained with hematoxylin and eosin in a-c; d was 
stained with PAS. 
in contrast to the significantly increased  amount of protein 
in the lungs of [3c to [3c transplanted animals. 
Donor Cell Repopulation of Recipient Lung Tissue.  To  fol- 
low  the  repopulation  of  recipient  animals  with  donor- 
derived  cells,  we  also  used  WT  donor  cells  that  allowed 
distinction  of  donor  versus  recipient  cell  populations  by 
FACS  |  analysis (see Materials and Methods). These WT do- 
nor cells, marked for identification  from recipient  cells,  re- 
versed  PAP  in  an  identical  fashion  to  the  above  experi- 
ments (data not shown).  In control stainings, WT  F1 donor 
(Ly 5.1  ￿  Ly 5.2)  and [3c mutant  (Ly 5.1) peripheral white 
blood cells showed uniform cell populations for the appro- 
priate  Ly  5  alleles  (Fig.  3,  control panels).  After WT  to  [3c 
mutant  animal  transplantation,  recipient  animals  contained 
predominant,  but  not  absolute,  donor  cell  phenotypes  in 
the peripheral  blood (Fig.  3, BMT WT-+[3c KO). The dis- 
tribution ofWT  F 1 donor  cells in the lung was followed by 
immunohistochemistry  of lung sections  using the  antibody 
against  Ly5.2.  Significant  numbers  of WT  Ly5.2-positive 
donor cells were detected in the lungs of [3c mutant recipients 
8  wk  after transfer  (Fig.  4  a),  whereas  [3c  to  [3c  (Ly  5.1) 
transplanted  animal  lung  sections  were  negative  for Ly5.2 
staining  (Fig. 4  b). The morphology and the location of the 
engrafting  Ly  5.2-positive  cells  suggested  alveolar  mac- 
rophage repopulation,  a cell type known to repopulate after 
bone marrow transplant  (8, 9).  Consistent with this finding 
was the  reversal of the  abnormal macrophage  morphology 
that  is  characteristic  for animals  undergoing  PAP.  Fig.  4  c 
shows alveolar macrophage morphology obtained from the 
BAL of normal unmanipulated  animals, a morphology sire- 
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Figure 2.  Pathological  evaluation  of the lungs of bone marrow-trans- 
planted animals. The genotype  of bone marrow donor and recipient ani- 
mals is shown  across the top.  (A) Evaluation  8 wk after transplant.  (/3) 
Evaluation 12 wk after transplant. In WT-WT and 13c KO-WT, two an- 
imals from each group were evaluated at 1 yr after transplantation and were 
included  to simplify presentation  of the data. All samples were blinded 
and randomized  before  evaluation.  Histopathological  categories were as 
follows. Category  1: no abnormalities observed.  Category  2: irfild multi- 
focal accumulation  of mononuclear cells around  bronchioles  and blood 
vasculature present in some areas; no intraalveolar material present. Cate- 
gory 3:  varying  degrees  of focal accumulations  of intraalveolar  macro- 
phages and/or type II pneumocytes.  Although these cells appear increased 
in number,  due to focal accumulation,  their general morphology is nor- 
mal. Occasional focal areas of interstitial fibrosis or collapsed alveolar septa 
are  present.  No  acellular intraalveolar  material  is present.  Category  4: 
~<90% of the alveolar space is filled with homogeneous PAS-positive and 
granular precipitate.  In some areas, the precipitate  is very densely packed. 
Numerous large vacuolated  macrophages  contain  the  granular  material 
and  have  a  foamy  appearance.  There  is  a  moderate  accumulation  of 
perivascular and peribronchiolar  mononuclear cells. Category 5: similar to 
category 4, except that the alveolar space is filled with exclusively densely 
packed amorphous  granular material that appears hyalinized. In addition, 
there are focal areas of necrosis and type II pneumocyte hyperplasia. The 
histopathological categories are not meant to indicate a linear scale of pa- 
thology, but rather reflect independent and distinct pathological findings. 
ilar to alveolar macrophages obtained from [3c mutant ani- 
mals after transplantion with WT bone marrow (Fig. 4  d), 
and in sharp  contrast to those obtained from [3c mutant an- 
imals still undergoing PAP  (Fig. 4  e). 
Given  that  transfer  of WT  bone  marrow  cells  into  [3c 
mutant  mice reversed the course of the lung disease,  transfer 
of ~c mutant  bone marrow into WT  animals may likewise 
be  expected  to  cause  the  disease  state.  However,  in  four 
Table  1.  Protein  Accumulation in BAL Fluid 
Group  Total protein in BAL 
WT unmanipulated  (n =  6) 
WT-I3c mutant  (n =  6) 
13c-13c mutant (n =  6) 
mg 
~<0.66  +  0.2 
~<0.64  +  0.083 
2.8  +  0.46 
Bone marrow from WT or 13c mutant animals was transplanted  into 13c 
mutant animals and 10 wk after transplantation  total protein content of 
BAL fluid was determined from each  group.  Similar results were ob- 
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Figure  3.  FACS  |  analysis of peripheral  blood  cells from control  or 
transplanted animals as described in Fig. 1. WT cells express both Ly 5.1 
and Ly 5.2, and 13c mutant  cells express only Ly 5.1. Each panel describes 
either  control  stalnings  or bone  marrow  transferred  and  reconstituted 
groups. 
mice evaluated  12 wk after transfer and in two mice evalu- 
ated  1 yr after transfer,  we were unable to detect the PAP- 
like disease  (Fig. 2).  The blood of these animals was repop- 
ulated by  donor  ]3c  mutant  cells,  as  evidenced by  FACS  | 
(Fig. 3, BMT  [3cKO-WT).  The cyto-ablative treatment  of 
the WT  recipients by  irradiation  may not  affect cell types 
such  as  terminally  differentiated  macrophages.  These  re- 
maining radio-resistant cells in the WT  animals may be suf- 
ficient  to  prevent  the  onset  of the  disease.  Alternatively, 
since bone marrow replacement was not  100%  (see Fig. 3), 
reseeding of the lung with WT  precursor  cells may be suf- 
ficient to prevent the disease. 
RAG-2 Mutant Donor Bone Marrow Reversed the PAP Dis- 
ease.  To  begin  to  evaluate  which  cell type  in  the  bone 
marrow  reversed  the  disease  state  in  the  lung,  we  used 
RAG-2 mutant mice as the source of donor cells. As RAG-2 
mutant  animals do not contain lymphocytes  (12),  the bone 
marrow from these animals are a source of donor cells more 
restricted to the myeloid lineage. Indeed, RAG-2 bone mar- 
row was able to reverse the PAP disease in [3c recipient an- 
imals  12  wk after transfer  (Fig.  2).  Animals showed  no in- 
traalveolar  substance,  identical  to  the  findings  of the  WT 
(whole bone marrow)  to 13c mutant animal transplantation. 
The  data  presented  in  this  report  document  that  whole 
bone  marrow  from normal  animals  or bone  marrow  from 
RAG-2 mutant  animals  can effectively reverse 13c-deficient 
PAP.  In previous  work we had  shown  that  grossly  abnor- 
mal alveolar macrophage morphology was a characteristic of 
mouse  13c-deficient  PAP  (6).  This  abnormal  morphology 
was  corrected  after engraftment  of donor-derived  myeloid 
lineages  into  the  lungs  of [3c  mutant  animals  after  bone 
2660  Bone Marrow Transplant Cures [3c-deficient Pulmonary Alveolar Proteinosis Figure 4.  (a and b) Evaluation of donor cell engraftment in the lungs 
of WT to [3c mutant transplanted animals. (a) Lung sections from a WT 
to 13c mutant transplantation were stained with an antibody specific for 
the Ly 5.2 allele, a cell surface marker for the donor cells. (b) A similar 
staining for lung sections from a 13c to [3c transplantation (uniformly Ly 
5.1).  (c-e) Morphology of alveolar macrophages from BAL. (c) Mac- 
rophages from unmanipulated WT animals. (d) Macrophages from WT 
to 13c transplantation. (e) Macrophages from 13c to 13c transplantation. 
marrow tranplantation, whether or not the donor bone mar- 
row contained the potential to develop lymphocytes. Taken 
together, these data indicate that a specialized alveolar mac- 
rophage  dysfunction  may  cause  this  disease.  A  reasonable 
hypothesis would be  a  requirement  of GM-CSF  stimula- 
tion of alveolar macrophages to  effectively process and/or 
degrade pulmonary surfactant. Observations of abnormal al- 
veolar macrophages have also been made in the human dis- 
ease state  (13,  14).  In support of this hypothesis, Huffrnan 
et al. (15) have recently described that transgenic expression 
of GM-CSF ligand by the  lung  tissue--specific SP-C  pro- 
moter corrected PAP when bred to GM-CSF ligand-defi- 
cient mice. 
In the studies reported here, we used ~c mutant recipi- 
ent animals that were  2-3-mo  old at the  time  of transfer, 
with  the  exception  of the  RAG-2  transplantation experi- 
ment  where  recipients were  7-too  old.  Considering  that 
intraalveolar debris is present at 2  mo and more pronounced 
at 7 mo in the natural course of the disease, these studies in- 
dicate that bone marrow transplantation can not only pre- 
vent  further  progression  of the  disease, but  also  reverse  a 
more established disease state. 
The ability of bone marrow to effectively reverse mouse 
PAP caused by loss of[3c expression is of significance to the 
human PAP disease state. A  subset of severely affected pe- 
diatric PAP patients has been identified with a  striking re- 
duction or absence of 13c protein expression at the cell sur- 
face (Dirksen, U., R. Nishinakamura, P. Groneck, L. Nogee, 
2661  Nishinakamura et al.  Brief Definitive Report R. Murray, and S. Burdach, manuscript submitted for pub- 
lication). Thus, a subset of humans with this disease, where 
cells are unresponsive  to  GM-CSF  by a  cell-autonomous 
mutation, may be a candidate for bone marrow transplanta- 
tion as a  means  of replacing the defective alveolar macro- 
phage  and reversing the  disease process.  Significantly, en- 
graftment of donor bone marrow into human recipients has 
been shown by Thomas et al. (10)  to result in donor-type 
alveolar macrophages when evaluated by lung biopsy samples. 
The  data presented here indicate that [3c-deficient mice 
will serve as a  useful model of the PAP disorder, and also 
emphasize  the  utility of bone  marrow  transplantation  to 
correct disease states that may not initially appear to be he- 
matopoietic in nature. 
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